ClinConnect ClinConnect Logo
Search / Trial NCT07015554

Serum IGF1 on Female HFpEF Patients

Launched by THE UNIVERSITY OF HONG KONG-SHENZHEN HOSPITAL · Jun 3, 2025

Trial Information

Current as of July 09, 2025

Enrolling by invitation

Keywords

Insulin Growth Factor (Igf1) Heart Failure With Preserved Ejection Fraction (H Fp Ef)

ClinConnect Summary

No description provided

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • age over 18;
  • female participants only;
  • Exclusion Criteria:
  • with congenital heart disease or with other family disease history
  • participants receiving hormone therapy

About The University Of Hong Kong Shenzhen Hospital

The University of Hong Kong-Shenzhen Hospital (HKU-SZH) is a leading clinical research institution dedicated to advancing healthcare through innovative medical research and trials. Established as a collaboration between the University of Hong Kong and the Shenzhen municipal government, the hospital integrates clinical practice, education, and research, fostering a multidisciplinary approach to patient care. HKU-SZH is committed to enhancing medical knowledge and improving treatment outcomes by conducting rigorous clinical trials across various therapeutic areas. With a focus on ethical standards and patient welfare, the hospital aims to contribute to the global medical community through impactful research and collaboration.

Locations

Shenzhen, Guangdong, China

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported